Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.

Choquette D, Bessette L, Alemao E, Haraoui B, Postema R, Raynauld JP, Coupal L.

Arthritis Res Ther. 2019 Jun 6;21(1):138. doi: 10.1186/s13075-019-1917-8.

2.

Development of a Canadian Core Clinical Dataset to Support High-quality Care for Canadian Patients with Rheumatoid Arthritis.

Barber CEH, Mosher DP, Ahluwalia V, Zummer M, Marshall DA, Choquette D, Lacaille D, Bombardier C, Lyddiatt A, Chandran V, Khodyakov D, Dao E, Barnabe C; RACCD Working Group.

J Rheumatol. 2017 Dec;44(12):1813-1822. doi: 10.3899/jrheum.170421. Epub 2017 Oct 1.

3.

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.

Weijers L, Baerwald C, Mennini FS, Rodríguez-Heredia JM, Bergman MJ, Choquette D, Herrmann KH, Attinà G, Nappi C, Merino SJ, Patel C, Mtibaa M, Foo J.

Rheumatol Int. 2017 Jul;37(7):1111-1123. doi: 10.1007/s00296-017-3739-9. Epub 2017 May 30.

4.

Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study.

Egeth M, Soosaar J, Nash P, Choquette D, Infante R, Ramey DR, Sahakian S, Lai A, Kim JJ, Wu D.

Adv Ther. 2017 May;34(5):1157-1172. doi: 10.1007/s12325-017-0523-x. Epub 2017 Apr 17.

5.

Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).

Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A.

Clin Rheumatol. 2017 Apr;36(4):773-779. doi: 10.1007/s10067-016-3505-5. Epub 2016 Dec 14.

PMID:
27966068
6.

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.

Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E, Santos MJ, Pavelka K, Turesson C, Mariette X, Choquette D, Hetland ML, Finckh A.

EBioMedicine. 2016 Sep;11:302-306. doi: 10.1016/j.ebiom.2016.08.024. Epub 2016 Aug 18.

7.

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.

Hughes PE, Rex K, Caenepeel S, Yang Y, Zhang Y, Broome MA, Kha HT, Burgess TL, Amore B, Kaplan-Lefko PJ, Moriguchi J, Werner J, Damore MA, Baker D, Choquette DM, Harmange JC, Radinsky R, Kendall R, Dussault I, Coxon A.

Mol Cancer Ther. 2016 Jul;15(7):1568-79. doi: 10.1158/1535-7163.MCT-15-0871. Epub 2016 Apr 19.

8.

Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.

Rahman P, Choquette D, Bensen WG, Khraishi M, Chow A, Zummer M, Shaikh S, Sheriff M, Dixit S, Sholter D, Psaradellis E, Sampalis JS, Letourneau V, Lehman AJ, Nantel F, Rampakakis E, Otawa S, Shawi M.

BMJ Open. 2016 Apr 5;6(4):e009661. doi: 10.1136/bmjopen-2015-009661.

9.

Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.

Boezio AA, Copeland KW, Rex K, K Albrecht B, Bauer D, Bellon SF, Boezio C, Broome MA, Choquette D, Coxon A, Dussault I, Hirai S, Lewis R, Lin MH, Lohman J, Liu J, Peterson EA, Potashman M, Shimanovich R, Teffera Y, Whittington DA, Vaida KR, Harmange JC.

J Med Chem. 2016 Mar 24;59(6):2328-42. doi: 10.1021/acs.jmedchem.5b01716. Epub 2016 Feb 11.

PMID:
26812066
10.

Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry.

Choquette D, Faraawi R, Chow A, Rodrigues J, Bensen WJ, Nantel F.

J Rheumatol. 2015 Jul;42(7):1105-11. doi: 10.3899/jrheum.140538. Epub 2015 Jun 15.

11.

Correction to Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors.

Peterson EA, Teffera Y, Albrecht BK, Bauer D, Bellon SF, Boezio A, Boezio C, Broome MA, Choquette D, Copeland KW, Dussault I, Lewis R, Lin MH, Lohman J, Liu J, Potashman M, Rex K, Shimanovich R, Whittington DA, Vaida KR, Harmange JC.

J Med Chem. 2015 May 14;58(9):4087. doi: 10.1021/acs.jmedchem.5b00591. Epub 2015 Apr 22. No abstract available.

PMID:
25901648
12.

Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.

Peterson EA, Teffera Y, Albrecht BK, Bauer D, Bellon SF, Boezio A, Boezio C, Broome MA, Choquette D, Copeland KW, Dussault I, Lewis R, Lin MH, Lohman J, Liu J, Potashman M, Rex K, Shimanovich R, Whittington DA, Vaida KR, Harmange JC.

J Med Chem. 2015 Mar 12;58(5):2417-30. doi: 10.1021/jm501913a. Epub 2015 Mar 3. Erratum in: J Med Chem. 2015 May 14;58(9):4087.

PMID:
25699405
13.

The challenge of indication extrapolation for infliximab biosimilars.

Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, Zou G, Xu Z, Shankar G, Sealey DC, Russell AS.

Biologicals. 2014 Jul;42(4):177-83. doi: 10.1016/j.biologicals.2014.05.005. Epub 2014 Jun 21. Review.

14.

Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents.

Bourré-Tessier J, Arino-Torregrosa M, Choquette D.

Clin Rheumatol. 2014 Aug;33(8):1049-53. doi: 10.1007/s10067-014-2528-z. Epub 2014 Feb 21.

PMID:
24554383
15.

Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.

Thorne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ, Kelsall JT, Lehman AJ, Shawi M, Khalil H, Nantel F, Rampakakis E, Sampalis JS, Otawa S.

Arthritis Care Res (Hoboken). 2014 Aug;66(8):1142-51. doi: 10.1002/acr.22290.

16.

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.

Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VM, Barile-Fabris L, Moots RJ, Ostor A, Andrianakos A, Gemmen E, Mpofu C, Chung C, Gylvin LH, Finckh A.

Ann Rheum Dis. 2015 Jun;74(6):979-84. doi: 10.1136/annrheumdis-2013-203993. Epub 2014 Jan 17.

17.

Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4-Year Long-Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate.

Raynauld JP, Martel-Pelletier J, Dorais M, Haraoui B, Choquette D, Abram F, Beaulieu A, Bessette L, Morin F, Wildi LM, Pelletier JP.

Cartilage. 2013 Jul;4(3):219-26. doi: 10.1177/1947603513483547.

18.

Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study.

Sieper J, Srinivasan S, Zamani O, Mielants H, Choquette D, Pavelka K, Loft AG, Géher P, Danda D, Reitblat T, Cantini F, Ancuta C, Erdes S, Raffayová H, Keat A, Gaston JS, Praprotnik S, Vastesaeger N.

Ann Rheum Dis. 2013 Oct;72(10):1621-7. doi: 10.1136/annrheumdis-2012-201777. Epub 2012 Oct 13.

PMID:
23065731
19.

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.

Peterson EA, Boezio AA, Andrews PS, Boezio CM, Bush TL, Cheng AC, Choquette D, Coats JR, Colletti AE, Copeland KW, DuPont M, Graceffa R, Grubinska B, Kim JL, Lewis RT, Liu J, Mullady EL, Potashman MH, Romero K, Shaffer PL, Stanton MK, Stellwagen JC, Teffera Y, Yi S, Cai T, La DS.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):4967-74. doi: 10.1016/j.bmcl.2012.06.033. Epub 2012 Jun 16.

PMID:
22765895
20.

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H, Epstein LF, Emkey R, Andrews PS, Yu VL, Saffran DC, Xu M, Drew A, Merkel P, Szilvassy S, Brake RL.

J Med Chem. 2012 Jul 26;55(14):6523-40. doi: 10.1021/jm3005866. Epub 2012 Jul 10.

PMID:
22734674
21.

Bioreactors to influence stem cell fate: augmentation of mesenchymal stem cell signaling pathways via dynamic culture systems.

Yeatts AB, Choquette DT, Fisher JP.

Biochim Biophys Acta. 2013 Feb;1830(2):2470-80. doi: 10.1016/j.bbagen.2012.06.007. Epub 2012 Jun 15. Review.

22.

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.

Bode CM, Boezio AA, Albrecht BK, Bellon SF, Berry L, Broome MA, Choquette D, Dussault I, Lewis RT, Lin MH, Rex K, Whittington DA, Yang Y, Harmange JC.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4089-93. doi: 10.1016/j.bmcl.2012.04.072. Epub 2012 Apr 25.

PMID:
22595176
23.

Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.

Liu L, Norman MH, Lee M, Xi N, Siegmund A, Boezio AA, Booker S, Choquette D, D'Angelo ND, Germain J, Yang K, Yang Y, Zhang Y, Bellon SF, Whittington DA, Harmange JC, Dominguez C, Kim TS, Dussault I.

J Med Chem. 2012 Mar 8;55(5):1868-97. doi: 10.1021/jm201331s. Epub 2012 Feb 24.

PMID:
22320327
24.

VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.

Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R, Xu J, Arnost M, Choquette D, Chen G, Zhou JH, Yao YM, Ball ED, Namchuk M, Davies RJ, Henkel G.

J Med Chem. 2012 Jan 26;55(2):725-34. doi: 10.1021/jm201198w. Epub 2012 Jan 5.

PMID:
22221201
25.

Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.

Davies RJ, Pierce AC, Forster C, Grey R, Xu J, Arnost M, Choquette D, Galullo V, Tian SK, Henkel G, Chen G, Heidary DK, Ma J, Stuver-Moody C, Namchuk M.

J Med Chem. 2011 Oct 27;54(20):7184-92. doi: 10.1021/jm200712h. Epub 2011 Oct 4.

PMID:
21970471
26.

Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation.

Raynauld JP, Martel-Pelletier J, Haraoui B, Choquette D, Dorais M, Wildi LM, Abram F, Pelletier JP; Canadian Licofelone Study Group.

Ann Rheum Dis. 2011 Aug;70(8):1382-8. doi: 10.1136/ard.2010.146407. Epub 2011 May 8.

PMID:
21551506
27.

Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.

Teffera Y, Choquette D, Liu J, Colletti AE, Hollis LS, Lin MH, Zhao Z.

Chem Res Toxicol. 2010 Nov 15;23(11):1743-52. doi: 10.1021/tx100208k. Epub 2010 Sep 8.

PMID:
20825217
28.

Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis.

Pelletier JP, Raynauld JP, Caron J, Mineau F, Abram F, Dorais M, Haraoui B, Choquette D, Martel-Pelletier J.

Ann Rheum Dis. 2010 Dec;69(12):2095-101. doi: 10.1136/ard.2009.122002. Epub 2010 Jun 22.

PMID:
20570834
29.

An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis.

Raynauld JP, Martel-Pelletier J, Beaulieu A, Bessette L, Morin F, Choquette D, Haraoui B, Abram F, Pelletier JP.

Semin Arthritis Rheum. 2010 Dec;40(3):185-92. doi: 10.1016/j.semarthrit.2009.10.003. Epub 2010 Feb 4.

PMID:
20132966
30.

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

Boezio AA, Berry L, Albrecht BK, Bauer D, Bellon SF, Bode C, Chen A, Choquette D, Dussault I, Fang M, Hirai S, Kaplan-Lefko P, Larrow JF, Lin MH, Lohman J, Potashman MH, Qu Y, Rex K, Santostefano M, Shah K, Shimanovich R, Springer SK, Teffera Y, Yang Y, Zhang Y, Harmange JC.

Bioorg Med Chem Lett. 2009 Nov 15;19(22):6307-12. doi: 10.1016/j.bmcl.2009.09.096. Epub 2009 Sep 27. Erratum in: Bioorg Med Chem Lett. 2010 Jan 15;20(2):773. Fang, Mei [added]; Qu, Yusheng [added].

PMID:
19819693
31.

Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept.

Bourré-Tessier J, Fortin C, Belisle A, Desmarais E, Choquette D, Senécal JL.

Scand J Rheumatol. 2009;38(4):311-6. doi: 10.1080/03009740902776935. Review.

PMID:
19444717
32.

Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis.

Raynauld JP, Martel-Pelletier J, Abram F, Dorais M, Haraoui B, Choquette D, Bias P, Emmert KH, Laufer S, Pelletier JP.

Arthritis Res Ther. 2008;10(6):R129. doi: 10.1186/ar2543. Epub 2008 Nov 5.

33.

A new non-invasive method to assess synovitis severity in relation to symptoms and cartilage volume loss in knee osteoarthritis patients using MRI.

Pelletier JP, Raynauld JP, Abram F, Haraoui B, Choquette D, Martel-Pelletier J.

Osteoarthritis Cartilage. 2008;16 Suppl 3:S8-13. doi: 10.1016/j.joca.2008.06.007. Epub 2008 Jul 30.

34.

Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI.

Raynauld JP, Martel-Pelletier J, Bias P, Laufer S, Haraoui B, Choquette D, Beaulieu AD, Abram F, Dorais M, Vignon E, Pelletier JP; Canadian Licofelone Study Group.

Ann Rheum Dis. 2009 Jun;68(6):938-47. doi: 10.1136/ard.2008.088732. Epub 2008 Jul 23.

PMID:
18653484
35.

Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties.

Choquette D, Teffera Y, Polverino A, Harmange JC.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4054-8. doi: 10.1016/j.bmcl.2008.05.114. Epub 2008 Jun 4.

PMID:
18573658
36.

Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.

Albrecht BK, Harmange JC, Bauer D, Berry L, Bode C, Boezio AA, Chen A, Choquette D, Dussault I, Fridrich C, Hirai S, Hoffman D, Larrow JF, Kaplan-Lefko P, Lin J, Lohman J, Long AM, Moriguchi J, O'Connor A, Potashman MH, Reese M, Rex K, Siegmund A, Shah K, Shimanovich R, Springer SK, Teffera Y, Yang Y, Zhang Y, Bellon SF.

J Med Chem. 2008 May 22;51(10):2879-82. doi: 10.1021/jm800043g. Epub 2008 Apr 22.

PMID:
18426196
37.

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

Harmange JC, Weiss MM, Germain J, Polverino AJ, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, DiPietro L, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Martin MW, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Wang L, White RD, Whittington DA, Zanon R.

J Med Chem. 2008 Mar 27;51(6):1649-67. doi: 10.1021/jm701097z. Epub 2008 Mar 7.

PMID:
18324761
38.

Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.

Weiss MM, Harmange JC, Polverino AJ, Bauer D, Berry L, Berry V, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Whittington DA, Zanon R.

J Med Chem. 2008 Mar 27;51(6):1668-80. doi: 10.1021/jm701098w. Epub 2008 Mar 7.

PMID:
18324759
39.

Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.

Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, Thomson GT, Beaulieu A, Choquette D, Maksymowych WP.

Arthritis Rheum. 2007 Dec;56(12):4005-14.

40.

Transdermal fentanyl improves pain control and functionality in patients with osteoarthritis: an open-label Canadian trial.

Choquette D, McCarthy TG, Rodrigues JF, Kelly AJ, Camacho F, Horbay GL, Husein-Bhabha FA.

Clin Rheumatol. 2008 May;27(5):587-95. Epub 2007 Nov 23.

PMID:
18038178
41.

The Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project.

Maksymowych WP, Gladman D, Rahman P, Boonen A, Bykerk V, Choquette D, Dimond S, Fortin P, Karsh J, Klinkhoff AV, Mosher D, Mulholland K, Olszynski WP, Russell AS, Savage L, Shanner L, Shojania K, Starr M, Thomson G, Zummer M, Inman R; Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada.

J Rheumatol. 2007 Nov;34(11):2273-84. Epub 2007 Sep 15.

PMID:
17896800
42.

Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?

Hunt RH, Choquette D, Craig BN, De Angelis C, Habal F, Fulthorpe G, Stewart JI, Turpie AG, Davis P.

Can Fam Physician. 2007 Jul;53(7):1177-84. Review.

43.

Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period.

Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Abram F, Choquette D, Haraoui B, Beary JF, Cline GA, Meyer JM, Pelletier JP.

Ann Rheum Dis. 2008 May;67(5):683-8. Epub 2007 Aug 29.

PMID:
17728333
44.

Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study.

Pelletier JP, Raynauld JP, Berthiaume MJ, Abram F, Choquette D, Haraoui B, Beary JF, Cline GA, Meyer JM, Martel-Pelletier J.

Arthritis Res Ther. 2007;9(4):R74.

45.

The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs.

Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senécal JL, Penrod JR, Joseph L, St Pierre Y, Pineau C, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM, Clarke AE; Tri-Nation Study Group.

Arthritis Rheum. 2007 Feb 15;57(1):64-70.

46.

Association of polymorphisms in the peroxisome proliferator-activated receptor gamma gene and osteoarthritis of the knee.

Cheng S, Afif H, Martel-Pelletier J, Benderdour M, Pelletier JP, Hilal G, Haraoui P, Raynauld JP, Choquette D, Fahmi H.

Ann Rheum Dis. 2006 Oct;65(10):1394-7.

47.

Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes.

Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Beaudoin G, Choquette D, Haraoui B, Tannenbaum H, Meyer JM, Beary JF, Cline GA, Pelletier JP.

Arthritis Res Ther. 2006;8(1):R21. Epub 2005 Dec 30.

48.

Impact of a general practitioner educational intervention on osteoarthritis treatment in an elderly population.

Rahme E, Choquette D, Beaulieu M, Bessette L, Joseph L, Toubouti Y, LeLorier J.

Am J Med. 2005 Nov;118(11):1262-70.

PMID:
16271911
49.

The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being.

Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, Penrod JR, Joseph L, St Pierre Y, Pineau C, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM, Clarke AE.

Rheumatology (Oxford). 2005 Jun;44(6):751-5. Epub 2005 Mar 9.

PMID:
15757968
50.

Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging.

Berthiaume MJ, Raynauld JP, Martel-Pelletier J, Labonté F, Beaudoin G, Bloch DA, Choquette D, Haraoui B, Altman RD, Hochberg M, Meyer JM, Cline GA, Pelletier JP.

Ann Rheum Dis. 2005 Apr;64(4):556-63. Epub 2004 Sep 16.

Supplemental Content

Loading ...
Support Center